Oral etoposide combined with oral arsenic plus retinoic acid for two cases with newly diagnosed high-risk acute promyelocytic leukemia during COVID19 pandemic

•Cytotoxic drug oral Vp-16 replace anthracyclines as cytoreductive agent at the initial stage of induction therapy for high-risk APL;.•Oral Vp-16 is convenient and it overcomes the limitation of intravenous chemotherapy drugs in some special circumstances;.•High-risk APL patients should receive oral Vp-16 as early as possible to reduce tumor load in order to secure safety of induction therapy.•It is indicated that pure oral induction regimen: oral etoposide, ATRA and RIF provides a novel effective therapy in outpatient clinics.